Keywords: USA, FDA, Recordati, Carbaglu, Genetic disordes, Actelion, Zavesca, Niemann-Pick disease

US FDA advisory panel back approval of Recordati’s Carbaglu and new use for Actelion’s Zavesca

Article | 15 January 2010

Print This

A US Food and Drug Administration advisory panel has unanimously recommended the approval of Italian drugmaker Recordati SpA's drug for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in